JAK Inhibitors and the Risk of Malignancy: A Meta-analysis Across Disease Indications
Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049
The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.
JAKi were associated with a higher incidence of malignancy compared with TNFi, but not compared with placebo or MTX. This association was driven primarily by the results of one large study, ORAL Surveillance.
It is worth noting that, overall, malignancies were rare events across all treatment groups.
Keywords:
